1203-45-8

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-2,3,8-TRIMETHYLQUINOLINE is used as a chemical intermediate in the synthesis of various drugs and active pharmaceutical ingredients, contributing to the development of new medications.
Used in Material Science:
In the field of material science, 4-CHLORO-2,3,8-TRIMETHYLQUINOLINE is utilized in the research and development of organic semiconductors and optoelectronic devices, owing to its unique chemical properties.
Used in Therapeutic Applications:
4-CHLORO-2,3,8-TRIMETHYLQUINOLINE is being investigated for its biological activity and potential as a therapeutic agent for various diseases and conditions, highlighting its versatility in the medical field.

Upstream product

• 95-53-4 o-toluidine 
• 609-14-3 2-acetylpropanoic acid ethyl ester 
• 1203-47-0 2,3,8-trimethylquinolin-4-ol 

Downstream Products

• 915722-79-1 N-(3-methylaminopropyl)-N'-(2,3,8-trimethylquinolin-4-yl)benzene-1,4-diamine 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Structure-activity relationship of quinoline derivatives as potent and selective α2c-adrenoceptor antagonists

Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human α2- adrenoceptor subtypes (α2A, α2B, and α2C). A number of compounds with good antagonist potencies against the α2C-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl)phenylamino]quinolin-3-yl}methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the α2c-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the α2C- adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.